IL7 and acute lymphoblastic leukemia: To further explore the therapeutic potential of CIGB-300 we next cultured primary T-ALL cells collected from pediatric patients at diagnosis (Table 1) for 48 h with or with IL-7 in the presence or absence of CIGB-300.